MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D

 
• By Alaric DeArment
  
female scientist working with microscope
MorphoSys is slimming down its R&D in relation to last year's acquisition of Constellation Pharmaceuticals • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D